Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients

BACKGROUND: Many immune checkpoint inhibitors (ICIs) have been approved in China to treat non‐small cell lung cancer (NSCLC). However, in the long term, less than 20% of patients benefit from ICIs. To maximize the benefit for NSCLC patients, it is necessary to guide the choice of immunotherapy throu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Thorac Cancer
Egile Nagusiak: Song, Peng, Yang, Dongliang, Wang, Hanping, Cui, Xiaoxia, Si, Xiaoyan, Zhang, Xiaotong, Zhang, Li
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons Australia, Ltd 2020
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7262920/
https://ncbi.nlm.nih.gov/pubmed/32329229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13442
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak